BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Blogs » BioWorld Perspectives » What’s in a Biotech Name? It’s Greek to Me

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

What’s in a Biotech Name? It’s Greek to Me

Oct. 13, 2011
By Jennifer Boggs

OK, you’re a biotech entrepreneur and you’ve found some interesting new technology. You’ve secured some seed funding, found some lab space and filled out all the appropriate paperwork for a business license. All’s that left to incorporate your brand new biotech start-up? A name.

Coming up with a good name is important. You need a name that speaks to your cause – and is easy to speak. After all, there will be many a presentation in your future, and you can’t afford to lose valuable time on pronunciation lessons.

But more than that, a good name is a way to impress other brainiacs in the biotech space, a way to show your colleagues that you’re more than a scientist – you’re a great reader of history and mythology, you appreciate art and opera, you are a sophisticate, you have traveled the world. Or maybe you just have a well-developed sense of irony. Or a serious yen for a really good pun.

I remember interviewing the CEO of a start-up company for BioWorld’s NewCo News series on AltraVax Inc. and, when I asked how the company got it’s the name, the CEO joked, “Well, it wasn’t easy. All the Greek gods and monsters were taken.”

Really, though, any Greek word will do, especially if there’s a connection to medicine. Here are some of my favorites:

2009 start-up Euthymics Bioscience Inc., named for a Greek word meaning “good mood,” appropriate since its lead program is in major depressive disorder;

Calithera Biosciences Inc., whose name comes from the Greek word “kallos,” meaning “harmony” or “symmetry”;

Ikaria Inc., named after the Greek island renowned for the healing qualities of its waters and home to the mythical Icarus;

U.S.-Chinese start-up Ascletis Inc., named after Asclepius, the Greek god of medicine;

Epiomed Therapeutics Inc., named by combining the Greek goddess of relieving pain, Epione, combined with the word “medicine”:

and execs at Oncothyreon Inc. doubled up on their Greek, combining the words for “tumor” and “shield” when creating its moniker.

There are many others. And, hey, Latin words are big, too. There’s Senex Biotechnology Inc., working on drugs for aging whose name means “old” in Latin. Aestus Therapeutics Inc.’s name comes from the Latin word meaning “passionate fire,” and Vicept Therapetuics Inc. combined “vita,” meaning life, and “receptus,” meaning to take back.

Sometimes founders pull from their own inspirations. For instance, I’ve talked to execs who christened their firms after their favorite sports teams (Chelsea Therapeutics Inc.), while others have gone for the names of locations or nearby towns (Coronado Biosciences Inc.)

And, sometimes, there seems a bit of a superstitious connection. When coming up with a name for his latest venture, biotech entrepreneur Alan Auerbach clearly is hoping to carry a little good will from his previous success with Cougar Biotechnology Inc. And it might be working. His new firm, Puma Biotechnology Inc. closed a $55 million private placement just last week. (Perhaps if Puma succeeds, Auerbach will return with Panther Biotechnology or Catamount Biotechnology.)

Clever names also make for some interesting partnerships as well. For instance, Ironwood Pharmaceuticals Inc., named after a hardwood tree, has a deal with Forest Laboratories Inc. There’s also the proofreader’s nightmare of a partnership between Clavis Pharma ASA and Clovis Oncology Inc.

And, seriously folks, am I the only one waiting with fingers crossed for a licensing deal uniting Osiris Therapeutics Inc. with its counterpart of Egyptian myth, Isis Pharmaceuticals Inc.? The geek-out headline potential alone would be more than worth it.

But that’s me.

Got a favorite biotech company name? We’d love to hear it!

 

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing